Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
Publication Date: June 4, 2019
Key Points
Key Points
Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin levels and reduces the need for red blood cell transfusions but increases the risk of thromboembolic events.
ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
Treatment
...reatment...
...epending on clinical circumstances ESAs may be...
...ot be offered to patients with che...
...uld not be offered to most patients w...
...offered to patients with lower risk myelodysplas...
...ents with myeloma, non-Hodgkin’s lymphoma,...
...ffering an ESA, clinicians should co...
...Panel considers epoetin beta and alfa, darb...
...ncrease the risk of thromboembolism, and clin...
It is recommended that starting and modifying dose...
...increased to the lowest concentration n...
...discontinued in patients who do not res...
...cement may be used to improve hemoglobin resp...
Table 1. Suggested Baseline Investigations fo...
...dult DosingHaving trouble viewing tabl...
...ble 3. Estimated Prices of ESAs and Supple...